COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02525380
Recruitment Status : Unknown
Verified January 2018 by Yoon Jun Kim, Seoul National University Hospital.
Recruitment status was:  Active, not recruiting
First Posted : August 17, 2015
Last Update Posted : January 17, 2018
BTG International Inc.
Information provided by (Responsible Party):
Yoon Jun Kim, Seoul National University Hospital

Brief Summary:
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinoma.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Procedure: Device(DC Bead) Phase 4

Detailed Description:

Transarterial chemoembolization (TACE) represents a first-line non-curative therapy for hepatocellular carcinoma (HCC). TACE is associated with unsatisfactory long-term outcomes. The objective response rate of TACE is only 15% to 55%, and the tumor recurrence rate is 70% at 5 years. One potential reason for this may be the increase in plasma vascular endothelial growth factor (VEGF) levels after TACE. Disturbances in the tumor microenvironment following TACE result in increased hypoxia, leading to an up-regulation in hypoxia inducible factor-1a, which in turn up-regulates VEGF and platelet-derived growth factor receptor (PDGFR) and increases tumor angiogenesis. TACE is considered for the patients with unresectable HCCs that are also ineligible for local ablative therapy. The lack of portal blood flow (because of portal vein thrombosis, portosystemic anastomoses or hepatofugal flow) had been considered as the main contraindication of TACE. However, it has been reported that TACE can be safely performed in a selected population of patients with main portal vein invasion, if they have well-preserved liver function due to collateral blood supply.

DC Beads are a novel drug delivery embolization system comprised of biocompatible, non-resorbable polyvinyl alcohol polymer hydrogel beads which can be loaded with cytotoxic drugs. The beads have a high affinity for drugs and this enables the gradual release of doxorubicin into the tumor, allowing a longer intratumoral exposure and less systemic exposure of the drug, reducing systemic toxicity. One multivariate analysis study showed that the median survival duration for the patients with portal vein invasion who were treated with DC-bead TACE (DEBDOX) were 176 days, retrospectively.

In international, multicenter, randomized phase II trial, the drug-eluting bead group showed higher rates of complete response and objective response compared with the cTACE group (27% vs. 22%, 52% vs. 44% respectively). The hypothesis of superiority was not met. However, patients with Child-Pugh B, ECOG 1, bilobar disease, and recurrent disease showed a significant increase in objective response compared to cTACE.

Here, the investigators will investigate the safety and efficacy of DC Bead TACE in patients with advanced HCC with portal vein invasion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC
Actual Study Start Date : September 2015
Actual Primary Completion Date : November 2017
Estimated Study Completion Date : August 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Doxorubicin loadeing-DC Bead(Device)

DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.

DC Bead is produced from polyvinyl alcohol.

Procedure: Device(DC Bead)
Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system

Primary Outcome Measures :
  1. The rate of Time to progression of hepatocellular carcinoma 30 patients. [ Time Frame: up to at least 3 years ]
    The rate of Time to progression of doxorubicin eluting bead embolization in patients with advanced hepatocellular carcinoma.After the treatment period, patients will undergo follow up for safety within 30 days (+7 days) of final DEBDOX, and will undergo follow up for survival every 84 days (±14 days) (84 days is the day counted from the DEBDOX TACE) for at least 3 years.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:[Stage C HCC according to the BarcelonaClinic of Liver Cancer]

  1. Signed written informed consent.
  2. Clinical or histological diagnosis of HCC based on the guidelines of the American Association for the Study of Liver Diseases.
  3. At least one typical enhanced lesion that is bi-dimensionally measurable by multiphasic spiral CT scan or dynamic contrast-enhanced MRI.
  4. Tumor conditions confirmed by abdominal imaging (contrast enhanced CT ± MRI) performed within 1 month prior to the enrollment:
  5. Age of at least 18 years and less than 80 years.
  6. ECOG Performance Status of 0 or 1.
  7. Child-Pugh class A or B (Child-Pugh score ≤ 7).
  8. Life expectancy of at least 16 weeks.
  9. Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements (no transfusion, no restoration), conducted within 14 days prior to screening:

    • Hemoglobin ≥ 8.0 g/dL
    • Absolute neutrophil count ≥ 1,000/mm3
    • Platelet count ≥ 50,000/μL
    • Total bilirubin <2.5 mg/dL
    • Serum albumin ≥2.8 g/dL
    • ALT and AST < 5 × upper limit of normal
    • PT-INR ≤ 2.3 or Prothrombin Time-sec ≤ 6 sec
    • Serum creatinine ≤ 1.7 mg/dL

Exclusion Criteria:

  1. A history of receiving any systemic therapy of the molecularly targeted agents, immunotherapy or cytotoxic chemotherapy for the treatment of HCC
  2. Invasion of inferior vena cava (Vv3), or invasion of first order branch of the biliary duct (B3)
  3. History or presence of hepatic encephalopathy
  4. Ascites, moderate, large or intractable
  5. Active clinically serious infections (> grade 2, NCI-CTC version 4.0), including spontaneous bacterial peritonitis.
  6. Untreated active chronic hepatitis B
  7. Esophageal or gastric varices≥ F2 (grade 2) with red color sign positive without prophylaxis (non-selective beta-blocker or endoscopic variceal ligation) or history of variceal bleeding without endoscopic variceal ligation/ injection sclerosis
  8. Active ulcer of stomach or duodenum: untreated or presence of visible vessel
  9. Any major surgery within 4 weeks, or any minor surgery within 2 weeks prior to signing the informed consent form
  10. Candidate for liver transplant and a history of liver transplantation
  11. History of cardiac disease: congestive heart failure greater than NYHA class 2; active coronary artery disease; cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension and diabetes mellitus
  12. History of AIDS/HIV infection.
  13. Seizure disorder requiring medication.
  14. History of organ allograft.
  15. Evidence or history of bleeding diathesis, or thromboembolic events requiring treatment
  16. Current renal dialysis.
  17. Previous or concurrent cancer that has a primary site or histology distinct from HCC, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis, and T1] or any cancer curatively treated less than 3 years prior to enrollment.
  18. History of alcohol abuse (male > 210g/week, female >140g/week)
  19. Any contraindication for chemoembolization except major branch of portal vein invasion
  20. Any contraindication for doxorubicin administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02525380

Layout table for location information
Korea, Republic of
Seoul National University
Seoul, Korea, Republic of, ASI|KR|KS013
Sponsors and Collaborators
Seoul National University Hospital
BTG International Inc.
Layout table for investigator information
Principal Investigator: Yoon Jun Kim, MD, PhD Seoul National University Hospital
Layout table for additonal information
Responsible Party: Yoon Jun Kim, Professor, Seoul National University Hospital Identifier: NCT02525380    
Other Study ID Numbers: DCbead_PVTT
First Posted: August 17, 2015    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018
Keywords provided by Yoon Jun Kim, Seoul National University Hospital:
Transarterial chemoembolization
Doxorubicin-Eluting-Bead Embolization
Hepatocellular carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases